



Living Cell Technologies Limited Company Announcement

Results of the Annual General Meeting held on 18 November 2010

18 November 2010: Sydney, Australia & Auckland, New Zealand. Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY), the following voting results are in respect of the resolutions laid before Members at the Annual General Meeting of Living Cell Technologies Ltd held today is provided in accordance with Listing Rule 3.13.2 and section 251AA (2) of the Corporations Act.

The Chairman announced that he would vote all undirected proxies in favour of all resolutions.

The total number of proxy votes exercisable by all proxies validly appointed was 93,417,443.

Resolution 1: Remuneration Report (non binding)

"That the Remuneration Report required by section 300A of the Corporations Act, as contained in the Directors' Report of the Company, for the year ended 30 June 2010 be adopted."

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	UNDIRECTED
65,895,390	11,000	10,240,213	17,270,840

Resolution 2: Re-election of Dr David Brookes

"That Dr David Brookes retires by rotation in accordance with Clause 6.1 of the Company's Constitution and being eligible, offers himself for re-election, be re-elected as a Director of the Company."

A poll was called on this resolution, the results of the poll were:

FOR	AGAINST	ABSTAIN
31,518,407	59,598,338	2,583,911

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	UNDIRECTED
14,912,247	59,598,338	2,571,911	16,334,947

Resolution 3: Re-election of Mr Simon O'Loughlin

"That Mr Simon O'Loughlin retires by rotation in accordance with Clause 6.1 of the Company's Constitution and being eligible, offers himself for re-election, be re-elected as a Director of the Company."

A poll was called on this resolution, the results of the poll were:

FOR	AGAINST	ABSTAIN
31,904,407	61,784,249	12,000

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	UNDIRECTED
15,298,247	61,784,249	-	16,334,947

Resolution 4: Ratification of Issue of Ordinary Shares Pursuant to ASX Listing Rule 7.4

"That, in accordance with ASX Listing Rule 7.4, the Company ratifies and approves for the purposes of ASX Listing Rule 7.1, the issue of 9,523,810 shares."

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	UNDIRECTED
63,880,770	57,873	13,143,853	16,334,947

Resolution 5: Approval to exempt from Listing Rule 7.1 Options issued under the Employee Share Option Plan in accordance with Exception 9 of Listing Rule 7.2

"That, for the purposes of ASX Listing Rule 7.2, the Company approves, as an exception to the 15% limit in Listing Rule 7.1, the issue from time to time of options to subscribe for ordinary shares in the Company to employees under the Employee Share Option Plan during the three year period commencing from 18 November 2010."

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	UNDIRECTED
61,601,246	40,873	15,440,377	16,334,947

Resolution 6: Approval of Issue of options to Dr Ross Macdonald in accordance with Listing Rule 10.11

“That approval be given pursuant to ASX Listing Rule 10.11 for the issue of 500,000 unlisted options over ordinary shares at a nil issue price to Dr Ross Macdonald.”

This resolution was passed on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	UNDIRECTED
60,828,631	6,720,575	10,210,340	16,334,947

- Ends -

For further information: www.lctglobal.com

<p>At the company: Ms Susanne Clay Chief Business Officer, Living Cell Technologies Tel: +64 9 270 7954 Mobile: +64 21 418 833 sclay@lctglobal.com</p>	<p>Media and investor enquiries: NZ and Australia: Buchan Consulting Rebecca Wilson Tel: +61 3 9866 4722 Mobile: +61 417 382 391 rwilson@bcg.com.au</p> <p>Paul Dekkers Tel: +612 9237 2800 pdekkers@bcg.com.au</p>
--	---

About Living Cell Technologies - www.lctglobal.com

Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with Type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The Company entered clinical trials for its diabetes product in 2007. For the treatment of Parkinson’s disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. LCT’s technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

LCT Disclaimer

This document contains certain forward-looking statements, relating to LCT’s business, which can be identified by the use of forward-looking terminology such as “promising,” “plans,” “anticipated,” “will”, “project”, “believe”, “forecast”,

“expected”, “estimated”, “targeting”, “aiming”, “set to,” “potential,” “seeking to,” “goal,” “could provide,” “intends,” “is being developed,” “could be,” “on track,” or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other health authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.